Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target upped by Evercore ISI from $41.00 to $48.00 in a research report issued to clients and investors on Monday, FlyOnTheWall reports. Evercore ISI’s target price would indicate a potential upside of 200.56% from the company’s previous close. A number of other research firms also […]
Oppenheimer initiated coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $40.00 price objective on the stock. A number of other research firms have also recently issued reports on CRNX. Robert W. Baird reduced their […]
Shares of Crinetics Pharmaceuticals Inc. gained more than 4% premarket on Thursday after Oppenheimer analysts initiated coverage of the shares with an.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective decreased by HC Wainwright from $35.00 to $33.00 in a research note issued to investors on Wednesday, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Crinetics Pharmaceuticals’ Q3 2023 earnings at ($0.83) EPS, Q4 2023 […]
Bourgeon Capital Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 56.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,150 shares of the company’s stock after buying an additional 1,500 shares during the quarter. […]